No Data
Express News | The Pacific Securities: The change in policies for generic drug formulations presents a good opportunity for the development of the Industry.
Express News | The National Healthcare Security Administration held a symposium on centralized volume-based procurement of pharmaceuticals.
Express News | Relevant departments, enterprises, and experts introduce information related to centralized procurement: the quality of Pharmaceutical products is strictly monitored, with comprehensive inspections of enterprises and random sampling of varieties.
Zhejiang Jingxin Pharmaceutical (002020.SZ): There are currently no plans to enter the Ophthalmology field.
Gelonghui December 26丨 Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company has no current plans to enter the Ophthalmology field.
Zhejiang Jingxin Pharmaceutical (002020.SZ): The company's diadizine is a globally innovative exclusive variety, with multiple patents still under protection.
Glory Financial, December 18 – Zhejiang Jingxin Pharmaceutical (002020.SZ) stated on the investor interaction platform that the company's dadarizine is a globally pioneering exclusive variety, and currently multiple patents are within the protection period.
Express News | Aspirin oral immediate-release dosage form 14 enters 7, Zhejiang Jingxin Pharmaceutical intends to be the first bidder.
No Data
